Exhibit
4.18


 


THE
REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT
EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR
HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING [●], 2022 (THE “EFFECTIVE DATE”)
TO ANYONE OTHER THAN (I) AEGIS CAPITAL CORP. OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING FOR WHICH THIS PURCHASE WARRANT WAS
ISSUED TO THE UNDERWRITER AS CONSIDERATION (THE “OFFERING”), OR (II) A BONA FIDE OFFICER OR PARTNER OF AEGIS
CAPITAL CORP.


 


THIS
PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO [●], 2022. VOID AFTER 5:00 P.M., EASTERN TIME, [●], 2027.


 


Common
Stock Purchase Warrant


 


For
the Purchase of [●] Shares of Common Stock


 


of


 


Curative
Biotechnology, Inc.


 


1.
Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of Aegis Capital Corp. (“Holder”),
as registered owner of this Purchase Warrant, to Curative Biotechnology, Inc., a Florida corporation (the “Company”),
Holder is entitled, at any time or from time to time beginning [●], 2022 (the “Commencement Date”), and
at or before 5:00 p.m., Eastern time, on [●], 2027 (the “Expiration Date”), but not thereafter, to subscribe
for, purchase and receive, in whole or in part, up to [●] shares of Common Stock of the Company, $0.0001 par value per share of
Common Stock (the “Common Stock”), subject to adjustment as provided in Section 6 hereof. If the Expiration
Date is not a Business Day, then this Purchase Warrant may be exercised on the next succeeding Business Day. During the period ending
on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is
initially exercisable at $[●] per share of Common Stock; provided, however, that upon the occurrence of any of the
events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per share of Common Stock
and the number of shares of Common Stock to be received upon such exercise, shall be adjusted as therein specified. The term “Exercise
Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context, and the term “Business
Day” shall mean a day other than a Saturday, Sunday or any other day which is a federal legal holiday in the United States
or any day on which the Federal Reserve Bank of New York is authorized or required by law or other governmental action to close, provided
that the Federal Reserve Bank of New York shall not be deemed to be authorized or obligated to be closed due to a “shelter in place,”
“non-essential employee” or similar closure of physical location at the direction of any governmental authority if the bank’s
electronic funds transfer systems (including for wire transfers) are open for use by customers on such day.


 


2.
Exercise.


 


2.1
Exercise Form. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed
and delivered to the Company, together with this Purchase Warrant and, subject to Section 2.2, payment of the Exercise Price for the
shares of Common Stock being purchased payable in cash by wire transfer of immediately available funds to an account designated by the
Company or by certified check or official bank check. If the subscription rights represented hereby shall not be exercised at or before
5:00 p.m., Eastern time, on the Expiration Date, this Purchase Warrant shall become and be void without further force or effect, and
all rights represented hereby shall cease and expire. Each exercise hereof shall be irrevocable.


 




    	 



    	 



    




 


2.2
Cashless Exercise. In lieu of exercising this Purchase Warrant by payment of cash or check payable to the order of the Company
pursuant to Section 2.1 above, Holder may elect to receive the number of shares of Common Stock equal to the value of this Purchase Warrant
(or the portion thereof being exercised), by surrender of this Purchase Warrant to the Company, together with the exercise form attached
hereto, in which event the Company will issue to Holder Shares in accordance with the following formula:


 





	X	=	Y(A-B)	 
	A	 


 


	Where,	 	 	 
	 	X	=	The
    number of shares of Common Stock to be issued to Holder;
	 	Y	=	The
    number of shares of Common Stock for which the Purchase Warrant is being exercised;
	 	A	=	The
    fair market value of one share of Common Stock; and
	 	B	=	The
    Exercise Price.


 


For
purposes of this Section 2.2, the fair market value of a share of Common Stock is defined as follows:


 


(i)
if the Company’s Common Stock are traded on a national securities exchange, the OTCQB or OTCQX, the fair market value shall be
deemed to be the closing price on such exchange, the OTCQB or OTCQX, as the case may be, on the Business Day immediately preceding the
date that the exercise form is delivered pursuant to Section 8.4 in connection with the exercise of the Purchase Warrant; or


 


(ii)
if the Company’s Common Stock are not then traded on a national securities exchange, the OTCQB or OTCQX and if prices for the Company’s
Common Stock are then reported on the “Pink Sheets” published by OTC Markets Group, Inc., the fair market value shall be
deemed to be the closing bid prior to the exercise form being submitted in connection with the exercise of the Purchase Warrant so reported;
provided, however, if there is no active public market, the value shall be the fair market value thereof, as determined in good faith
by the Company’s Board of Directors.


 


2.3
Legend. Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such securities
have been registered under the Securities Act of 1933, as amended (the “Act”):


 


The
securities represented by this certificate have not been registered under the Securities Act of 1933, as amended (the “Act”),
or applicable state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred except
pursuant to an effective registration statement under the Act, or pursuant to an exemption from registration under the Act and applicable
state law which, in the opinion of counsel to Curative Biotechnology, Inc., is available.


 


2.4
Resale of Common Stock. Holder and the Company acknowledge that as of the date hereof the Staff of the Division of Corporation
Finance of the SEC has published Compliance & Disclosure Interpretation 528.04 in the Securities Act Rules section thereof, stating
that the holder of securities issued in connection with a public offering may not rely upon Rule 144 promulgated under the Act to establish
an exemption from registration requirements under Section 4(a)(1) under the Act, but may nonetheless apply Rule 144 constructively for
the resale of such shares in the following manner: (a) provided that six months has elapsed since the last sale under the registration
statement, an underwriter or finder may resell the securities in accordance with the provisions of Rule 144(c), (e), and (f), except
for the notice requirement; (b) a purchaser of the shares from an underwriter receives restricted securities unless the sale is made
with an appropriate, current prospectus, or unless the sale is made pursuant to the conditions contained in (a) above; (c) a purchaser
of the shares from an underwriter who receives restricted securities may include the underwriter’s holding period, provided that
the underwriter or finder is not an affiliate of the issuer; and (d) if an underwriter transfers the shares to its employees, the employees
may tack the firm’s holding period for purposes of Rule 144(d), but they must aggregate sales of the distributed shares with those
of other employees, as well as those of the underwriter or finder, for a six-month period from the date of the transfer to the employees.
Holder and the Company also acknowledge that the Staff of the Division of Corporation Finance of the SEC has advised in various no-action
letters that the holding period associated with securities issued without registration to a service provider commences upon the completion
of the services, which the Company agrees and acknowledges shall be the final closing of the Offering, and that Rule 144(d)(3)(ii) provides
that securities acquired from the issuer solely in exchange for other securities of the same issuer shall be deemed to have been acquired
at the same time as the securities surrendered for conversion (which the Company agrees is the date of the initial issuance of this Purchase
Warrant). In the event that following a reasonably-timed written request by Holder to transfer the shares of Common Stock in accordance
with Compliance & Disclosure Interpretation 528.04 counsel for the Company in good faith concludes that Compliance & Disclosure
Interpretation 528.04 no longer may be relied upon as a result of changes in applicable laws, regulations, or interpretations of the
SEC Division of Corporation Finance, or as a result of judicial interpretations not known by the Company or its counsel on the date hereof
(either, a “Registration Trigger Event”), then the Company shall promptly, and in any event within five (5)
Business Days following the request, provide written notice to Holder of such determination. As a condition to giving such notice, the
parties shall negotiate in good faith a single demand registration right pursuant to an agreement in customary form reasonably acceptable
to the parties; provided that notwithstanding anything to the contrary, the obligations of the Company pursuant to this Section 2 shall
terminate on the fifth anniversary of the commencement of sales of the public offering. In the absence of such conclusion by counsel
for the Company, the Company shall, upon such a request of Holder given no earlier than six months after the final closing of the Offering,
instruct its transfer agent to permit the transfer of such shares in accordance with Compliance & Disclosure Interpretation 528.04,
provided that Holder has provided such documentation as shall be reasonably be requested by the Company to establish compliance with
the conditions of Compliance & Disclosure Interpretation 528.04. Notwithstanding anything to the contrary, pursuant to FINRA Rule
5110(g)(8)(A), the Holder shall not be entitled to more than one demand registration right hereunder and the duration of the registration
rights hereunder shall not exceed five years from the commencement of sales of the public offering.


 




    	 



    	 



    

 





3.
Transfer.


 


3.1
General Restrictions. The registered Holder of this Purchase Warrant agrees by such Holder’s acceptance hereof, that such
Holder will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant for a period of one hundred eighty (180) days
following the Effective Date to anyone other than: (i) Holder or an underwriter, placement agent, or a selected dealer participating
in the Offering, or (ii) a bona fide officer or partner of Holder or of any such underwriter, placement agent or selected dealer, in
each case in accordance with FINRA Conduct Rule 5110(g)(1), or (b) for a period of one hundred eighty (180) days following the Effective
Date cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale, derivative, put or
call transaction that would result in the effective economic disposition of this Purchase Warrant or the securities hereunder, except
as provided for in FINRA Rule 5110(g)(2). After 180 days after the Effective Date, transfers to others may be made subject to compliance
with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver to the Company
the assignment form attached hereto duly executed and completed, together with the Purchase Warrant and payment of all transfer taxes,
if any, payable in connection therewith. The Company shall within five (5) Business Days transfer this Purchase Warrant on the books
of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate assignee(s)
expressly evidencing the right to purchase the aggregate number of shares of Common Stock purchasable hereunder or such portion of such
number as shall be contemplated by any such assignment.


 


3.2
Restrictions Imposed by the Act. The securities evidenced by this Purchase Warrant shall not be transferred unless and until:
(i) if required by applicable law, the Company has received the opinion of counsel for the Company that the securities may be transferred
pursuant to an exemption from registration under the Act and applicable state securities laws, or (ii) a registration statement or a
post-effective amendment to the Registration Statement relating to the offer and sale of such securities has been filed by the Company
and declared effective by the U.S. Securities and Exchange Commission (the “Commission”) and compliance with
applicable state securities law has been established.


 


4.
Piggyback Registration Rights.


 


4.1
Grant of Right. In the event that there is not an effective registration statement covering the Purchase Warrant or the underlying
shares of Common Stock, whenever the Company proposes to register any of its Common Stock under the Act (other than (i) a registration
effected solely to implement an employee benefit plan or a transaction to which Rule 145 of the Act is applicable, or (ii) a registration
statement on Form S-4, S-8 or any successor form thereto or another form not available for registering the shares of Common Stock issuable
upon exercise of this Purchase Warrant for sale to the public, whether for its own account or for the account of one or more stockholders
of the Company (a “Piggyback Registration”), the Company shall give prompt written notice (in any event no
later than ten (10) Business Days prior to the filing of such registration statement) to the Holder of the Company’s intention
to effect such a registration and, subject to the remaining provisions of this Section 4.1, shall include in such registration such number
of shares of Common Stock underlying this Purchase Warrant (the “Registrable Securities”) that the Holders
have (within ten (10) Business Days of the respective Holder’s receipt of such notice) requested in writing (including such number)
to be included within such registration. If a Piggyback Registration is an underwritten offering and the managing underwriter advises
the Company that it has determined in good faith that marketing factors require a limit on the number of shares of Common Stock to be
included in such registration, including all shares of Common Stock issuable upon exercise of this Purchase Warrant (if the Holder has
elected to include such shares in such Piggyback Registration) and all other Common Stock proposed to be included in such underwritten
offering, the Company shall include in such registration (i) first, the number of shares of Common Stock that the Company proposes to
issue and sell pursuant to such underwritten offering and (ii) second, the number of shares of Common Stock, if any, requested to be
included therein by selling stockholders (including the Holder) allocated pro rata among all such persons on the basis of the number
of shares of Common Stock then owned by each such person. If any Piggyback Registration is initiated as a primary underwritten offering
on behalf of the Company, the Company shall select the investment banking firm or firms to act as the managing underwriter or underwriters
in connection with such offering. Notwithstanding anything to the contrary, the obligations of the Company pursuant to this Section 4.1
shall terminate on the earlier of (i) the fifth anniversary of the Effective Date and (ii) the date that Rule 144 would allow the Holder
to sell its Registrable Securities during any ninety (90) day period, and shall not be applicable so long as the Company’s Registration
Statement on Form S-1 (No. 333-263715 covering the Registrable Securities remains effective at such time. The duration of the piggyback
registration right shall not exceed seven years from the commencement of sales of the public offering.


 




    	 



    	 



    




 


4.2
Indemnification. The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration
statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Act or Section 20 (a)
of the Securities Exchange Act of 1934, as amended (“Exchange Act”), against all loss, claim, damage, expense
or liability (including all reasonable attorneys’ fees and other out-of-pocket expenses reasonably incurred in investigating, preparing
or defending against any claim whatsoever) to which any of them may become subject under the Act, the Exchange Act or otherwise, arising
from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which the Company
has agreed to indemnify Holder contained in the Underwriting Agreement between Holder and the Company, dated as of [●], 2022. The
Holder(s) of the Registrable Securities to be sold pursuant to such registration statement, and their successors and assigns, shall severally,
and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys’
fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may
become subject under the Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their
successors or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect
as the provisions contained in the Underwriting Agreement pursuant to which Holder has agreed to indemnify the Company.


 


4.3
Exercise of Purchase Warrants. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise
their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.


 


4.4
Documents Delivered to Holders. The Company shall deliver promptly to each Holder participating in the offering requesting the
correspondence and memoranda described below, copies of all correspondence between the Commission and the Company, its counsel or auditors
and all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each
Holder and underwriter to do such investigation, upon reasonable advance notice, with respect to information contained in or omitted
from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation
shall include access to books, records and properties and opportunities to discuss the business of the Company with its officers and
independent auditors, all to such reasonable extent and at such reasonable times, during normal business hours, as any such Holder shall
reasonably request.


 


4.5
Underwriting Agreement. The Holders shall be parties to any underwriting agreement relating to a Piggyback Registration. Such
Holders shall not be required to make any representations or warranties to or agreements with the Company or the underwriters except
as they may relate to such Holders, their shares of Common Stock and the amount and nature of their ownership thereof and their intended
methods of distribution.


 


4.6
Documents to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to
the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security
holders.


 




    	 



    	 



    

 





4.7
Damages. Should the Company fail to comply with such provisions, the Holder(s) shall, in addition to any other legal or other
relief available to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against
the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and
without the necessity of posting bond or other security.


 


5.
New Purchase Warrants to be Issued.


 


5.1
Partial Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned
in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation,
together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax if exercised
pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor
to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number of shares of Common Stock
purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.


 


5.2
Lost Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of
this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, determined in the sole discretion of the
Company, the Company shall execute and deliver a new Purchase Warrant of like tenor and date. Any such new Purchase Warrant executed
and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the
part of the Company.


 


6.
Adjustments.


 


6.1
Adjustments to Exercise Price and Number of Securities. The Exercise Price and the number of shares of Common Stock underlying
the Purchase Warrant shall be subject to adjustment from time to time as hereinafter set forth:


 


6.1.1
Share Dividends; Split Ups. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding
shares of Common Stock is increased by a stock dividend payable in shares of Common Stock or by a split up of shares of Common Stock
or other similar event, then, on the effective day thereof, the number of shares of Common Stock purchasable hereunder shall be increased
in proportion to such increase in outstanding shares of Common Stock, and the Exercise Price shall be proportionately decreased.


 


6.1.2
Aggregation of Common Stock. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding
shares of Common Stock is decreased by a consolidation, combination or reclassification of shares of Common Stock or other similar event,
then, on the effective date thereof, the number of shares of Common Stock purchasable hereunder shall be decreased in proportion to such
decrease in outstanding shares of Common Stock, and the Exercise Price shall be proportionately increased.


 


6.1.3
Replacement of Securities upon Reorganization, Etc. In case of any reclassification or reorganization of the outstanding shares
of Common Stock other than a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the par value of such shares of Common
Stock, or in the case of any share reconstruction or amalgamation or consolidation or merger of the Company with or into another corporation
(other than a consolidation or share reconstruction or amalgamation or merger in which the Company is the continuing company and that
does not result in any reclassification or reorganization of the outstanding shares of Common Stock), or in the case of any sale or conveyance
to another corporation or entity of the property of the Company as an entirety or substantially as an entirety in connection with which
the Company is dissolved, the Holder of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise
of this Purchase Warrant) to receive upon the exercise hereof, for the same aggregate Exercise Price payable hereunder immediately prior
to such event, the kind and amount of shares or other securities or property (including cash) receivable upon such reclassification,
reorganization, share reconstruction or amalgamation, or consolidation, or upon a dissolution following any such sale or transfer, by
a Holder of the number of shares of Common Stock of the Company obtainable upon exercise of this Purchase Warrant immediately prior to
such event; and if any reclassification also results in a change in shares of Common Stock covered by Section 6.1.1 or 6.1.2, then such
adjustment shall be made pursuant to Sections 6.1.1, 6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly
apply to successive reclassifications, reorganizations, share reconstructions or amalgamations, or consolidations, sales or other transfers.


 




    	 



    	 



    

 





6.1.4
Changes in Form of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to this
Section 6.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of shares of Common
Stock as are stated in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance
of new Purchase Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an adjustment occurring
after the Commencement Date or the computation thereof.


 


6.2
Substitute Purchase Warrant. In case of any consolidation of the Company with, or share reconstruction or amalgamation or merger
of the Company with or into, another corporation (other than a consolidation or share reconstruction or amalgamation or merger which
does not result in any reclassification or change of the outstanding shares of Common Stock), the corporation formed by such consolidation
or share reconstruction or amalgamation shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder
of each Purchase Warrant then outstanding or to be outstanding shall have the right thereafter (until the stated expiration of such Purchase
Warrant) to receive, upon exercise of such Purchase Warrant, the kind and amount of shares and other securities and property receivable
upon such consolidation or share reconstruction or amalgamation, by a holder of the number of shares of Common Stock of the Company for
which such Purchase Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation or
merger, sale or transfer. Such supplemental Purchase Warrant shall provide for adjustments which shall be identical to the adjustments
provided for in this Section 6. The above provision of this Section shall similarly apply to successive consolidations or share reconstructions
or amalgamations or mergers.


 


6.3
Elimination of Fractional Interests. The Company shall not be required to issue certificates representing fractions of shares
of Common Stock upon the exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional
interests, it being the intent of the parties that all fractional interests shall be eliminated by rounding any fraction up or down,
as the case may be, to the nearest whole number of shares of Common Stock or other securities, properties or rights.


 


7.
Reservation. The Company shall at all times reserve and keep available out of its authorized shares of Common Stock, solely for
the purpose of issuance upon exercise of the Purchase Warrants, such number of shares of Common Stock or other securities, properties
or rights as shall be issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants
and payment of the Exercise Price therefor, in accordance with the terms hereby, all shares of Common Stock and other securities issuable
upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder.


 


8.
Certain Notice Requirements.


 


8.1
Holder’s Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holder the right to vote or consent
or to receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder
of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events described
in Section 8.2 shall occur, then, in one or more of said events, the Company shall deliver to each Holder a copy of each notice relating
to such events given to the other shareholders of the Company at the same time and in the same manner that such notice is given to the
shareholders.


 


8.2
Events Requiring Notice. The Company shall be required to give the notice described in this Section 8 upon one or more of the
following events: (i) if the Company shall take a record of the holders of its shares of Common Stock for the purpose of entitling them
to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of
retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company, or (ii) the
Company shall offer to all the holders of its shares of Common Stock any additional shares of capital stock of the Company or securities
convertible into or exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor.


 


8.3
Notice of Change in Exercise Price. The Company shall, within 3 Business Days after an event requiring a change in the Exercise
Price pursuant to Section 6 hereof, send notice to the Holders of such event and change (“Price Notice”). The
Price Notice shall describe the event causing the change and the method of calculating same.


 




    	 



    	 



    

 





8.4
Transmittal of Notices. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing
and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service to following addresses or to such other
address as the Holder or the Company may designate by notice to the other party and shall be deemed given and effective on the earliest
of (i) the time of transmission, if such notice or communication is delivered via e-mail (with confirmation of receipt from the intended
recipient by return e-mail or other written acknowledgment) at the e-mail address set forth in this Section prior to 5:30 p.m. (New York
City time) on any date, (ii) the next Business Day after the time of transmission, if such notice or communication is delivered via e-mail
(with confirmation of receipt from the intended recipient by return email or other written acknowledgment) at the e-mail address set
forth in this Section on a day that is not a Business Day or later than 5:30 p.m. (New York City time) on any Business Day, (iii) the
second Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual
receipt by the party to whom such notice is required to be given:


 


If
to the Holder:


 


Aegis
Capital Corp.,


810
Seventh Avenue, 18th Floor,


New
York, NY 10019,


Attention:
Global Equity Markets


 


with
a copy (which shall not constitute notice) to:


 


Anthony
W. Basch, Esq.


Kaufman
& Canoles, P.C.


1021
E. Cary Street, Suite 1400


Two
James Center


Richmond,
VA 23219


E-mail:
awbasch@kaufcan.com


 


If
to the Company:


 


Curative
Biotechnology, Inc.

1825 NW Corporate Blvd, Suite 110


Boca
Raton, FL 33431


Attention:
I. Richard Garr Chief Executive Officer


E-mail:
irgarr@curativebiotech.com


 


with
a copy (which shall not constitute notice) to:


 


Silvestre
Law Group, P.C.


Raul
Silvestre, Esq.


2629
Townsgate Rd., Suite 215


Westlake
Village, CA 91362


E-mail:
rsilvestre@silvestrelaw.com


 


9.
Miscellaneous.


 


9.1
Amendments. The Company and Holder may from time to time supplement or amend this Purchase Warrant without the approval of any
of the Holders in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent
with any other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company
and Holder may deem necessary or desirable and that the Company and Holder deem shall not adversely affect the interest of the Holders.
All other modifications or amendments shall require the written consent of and be signed by (i) the Company and (ii) the Holder(s) of
Purchase Warrants then-exercisable for at least a majority of the Common Stock then-exercisable pursuant to all then-outstanding Purchase
Warrants.


 




    	 



    	 



    

 





9.2
Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or
affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant.


 


9.3.
Entire Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection
with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and supersedes
all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.


 


9.4
Binding Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company
and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions
herein contained.


 


9.5
Governing Law; Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced
in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby
agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant shall be brought
and enforced in the courts located in the City of New York, County of New York, and State of New York, and irrevocably submits to such
jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that
such courts represent an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting a copy
thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section
8 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or
claim. The Company and the Holder agree that the prevailing party(ies) in any such action shall be entitled to recover from the other
party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection
with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders
and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.


 


9.6
Non-Waiver. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall
not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any
provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No
waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set
forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver
of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach,
non-compliance or non-fulfillment.


 


9.7
Exchange Agreement. As a condition of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that,
at any time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and Holder enter into an agreement (“Exchange
Agreement”) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash
or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.


 


[Signature
Page Follows]


 




    	 



    	 



    




 


IN
WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly authorized officer as of the date first written
above.


 


Curative
Biotechnology, Inc.


 


	By:	 	 
	Name:	I.
    Richard Garr	 
	Title:	Chief
    Executive Officer	 


 




    	 



    	 



    

 


[Form
to be used to exercise Purchase Warrant]


 


Date:
__________, 20___


 


The
undersigned hereby elects irrevocably to exercise the Purchase Warrant for ______ shares of Common Stock, $0.0001 par value per share
of Common Stock (the “Common Stock”), of Curative Biotechnology, Inc., a Florida corporation (the “Company”),
and hereby makes payment of $____ (at the rate of $____ per Share) in payment of the Exercise Price pursuant thereto. Please issue the
shares of Common Stock as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable,
a new Purchase Warrant representing the number of shares of Common Stock for which this Purchase Warrant has not been exercised.


 


or


 


The
undersigned hereby elects irrevocably to convert its right to purchase ___ shares of Common Stock of the Company under the Purchase Warrant
for ______ shares of Common Stock, as determined in accordance with the following formula:


 


	  	X	=	Y(A-B)	 
	 	 	 	A	 



 


	Where,	  	  	  
	  	X	=	The
    number of shares of Common Stock to be issued to Holder;
	  	Y	=	The
    number of shares of Common Stock for which the Purchase Warrant is being exercised;
	  	A	=	The
    fair market value of one share of Common Stock which is equal to $_____; and
	  	B	=	The
    Exercise Price which is equal to $______ per share of Common Stock
	  	  	  	  


The
undersigned agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement
with respect to the calculation shall be resolved by the Company in its sole discretion.


 


Please
issue the shares of Common Stock as to which this Purchase Warrant is exercised in accordance with the instructions given below and,
if applicable, a new Purchase Warrant representing the number of shares of Common Stock for which this Purchase Warrant has not been
converted.


 


	  	Signature	  	 
	  	  	  
	  	Signature
    Guaranteed	  	 


 


	INSTRUCTIONS FOR REGISTRATION OF SECURITIES   
	  	  
	Name:  	  
	 	(Print
    in Block Letters)
	  	  
	Address:  	  
	  	  


 


NOTICE:
The signature to this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange.


 




    	 



    	 



    




 


[Form
to be used to assign Purchase Warrant]


 


ASSIGNMENT


 


(To
be executed by the registered Holder to effect a transfer of the within Purchase Warrant):


 


FOR
VALUE RECEIVED, __________________ does hereby sell, assign and transfer unto the right to purchase ordinary shares, no par value per
share, of Curative Biotechnology, Inc., a Florida corporation (the “Company”), evidenced by the Purchase Warrant
and does hereby authorize the Company to transfer such right on the books of the Company.


 


Dated:
__________, 20__


 


	Signature	 
	Signature
    Guaranteed	 	 


 


NOTICE:
The signature to this form must correspond with the name as written upon the face of the within Purchase Warrant without alteration or
enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm
having membership on a registered national securities exchange.